Herpes Simplex Virus Infection
8
0
0
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
85.7%
-0.8% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2
Host RNA Expression Profiles and Protein Biomarkers in Neonatal Herpes Simplex Virus Infection
Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis
Pharmacokinetics of Valacyclovir Oral Solution in Children
Oral and Perioral Herpes Simplex Virus Infection Type I in a Five-month-old Infant: A Case Report
Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir
Palatability Testing of a New Paediatric Formulation of Valacyclovir
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers